Connection

Paolo Maggi to Anti-HIV Agents

Back to Details
This is a "connection" page, showing publications Paolo Maggi has written about Anti-HIV Agents.
Paolo Maggi
Connection Strength
0.691
Anti-HIV Agents
  1. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017 08 09; 17(1):551.
    View in: PubMed
    Score: 0.277
  2. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort. Atherosclerosis. 2017 08; 263:398-404.
    View in: PubMed
    Score: 0.272
  3. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
    View in: PubMed
    Score: 0.074
  4. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.